Sanjeeva Srivastava
IIT Bombay, India
Title: Discovery and Validation of Biomarkers for Gliomas using mass spectrometry based quantitative and targeted proteomics
Biography
Biography: Sanjeeva Srivastava
Abstract
Glioma brain tumors arise from glial cells. Glioblastoma multiforme (GBM) is the most common and most malignant of the glial tumors. We have performed a comprehensive iTRAQ-based quantitative tissue proteomic analysis of gliomas and compared it with different controls, including other cancer samples as disease control to identify differentially expressed proteins in different groups of brain tumors. The iTRAQ-labeled peptides were fractionated using off-gel fractionation followed by LC-MS/MS analysis. Various metabolic pathways including fructose & mannose metabolism, spliceosome and aminoacid metabolism were found to be altered in GBM, medulloblastoma and meningiomas respectively. Proteins like CRYAB, GFAP, BASP1 and SNCA were found to be significantly altered in gliomas, where as VIM, RABP1, ANXA2 and SBP1 showed differential expression in meningiomas. Protein biomarkers identified from discovery-phase were further validated using MRM-based quantitative approach. Targeted proteomics data was analyzed using Skyline and for each protein a minimum of 3 peptides with at least 3 corresponding transitions were used for quantification. The in-solution digested peptides from the tissue lysates were run on triple quadrupole mass spectrometry. This comprehensive mass spectrometry based quantitative and targeted proteomic profiling of brain tumors identified few potential markers and provided insights into tumor pathophsyiology.